Immunic (IMUX) Stock Price, News & Analysis

Company Overview

Immunic, Inc. (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for chronic inflammatory and neurodegenerative diseases. The company’s research programs are designed to address conditions affecting the immune system and central nervous system, including multiple sclerosis and selected gastrointestinal disorders.

Immunic’s lead investigational product is vidofludimus calcium, also known as IMU-838, a selective oral inhibitor of the enzyme dihydroorotate dehydrogenase. The therapy has been evaluated in clinical studies for relapsing and progressive forms of multiple sclerosis. Immunic is also advancing earlier-stage programs, including oral drug candidates intended to modulate biological pathways involved in intestinal disease and tissue repair.

The company was established in 2016 and operates internationally, with corporate activities in the United States and research and development operations in Europe, particularly Germany. Immunic is led by Chief Executive Officer and co-founder Daniel Vitt, Ph.D. Its products remain investigational, and the company does not currently have an approved commercial product.

Key Stats

• Today's Range: $9.12 to $9.50
• 50-Day Range: $9.32 to $16.90
• 52-Week Range: $5.06 to $17.43
• Volume: 316,334 shs
• Average Volume: 287,097 shs
• Market Capitalization: $127.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.25
• Consensus Rating: Buy

Immunic Stock Analysis - MarketRank™

Immunic scored higher than 62% of companies evaluated by MarketBeat, and ranked 336th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Immunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Immunic has a consensus price target of $47.25, representing about 411.4% upside from its current price of $9.24.

Amount of Analyst Coverage

Immunic has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immunic are expected to grow in the coming year, from ($3.71) to ($2.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunic is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunic is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.92% of the float of Immunic has been sold short.

Short Interest Ratio / Days to Cover

Immunic has a short interest ratio ("days to cover") of 5.04.

Change versus previous month

Short interest in Immunic has recently increased by 20.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunic does not currently pay a dividend.

Dividend Growth

Immunic does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Immunic has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Immunic this week, compared to 4 articles on an average week.

Search Interest

Only 10 people have searched for IMUX on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immunic insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.49% of the stock of Immunic is held by insiders.

Percentage Held by Institutions

51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IMUX
• CIK: 1280776
• Web: www.imux.com
• Phone: (332) 255-9818
• Fax: 858-673-6843
• Employees: 95
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Immunic: $47.25
• High Price Target: $130.00
• Low Price Target: $19.00
• Potential Upside/Downside: +405.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$97.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -157.89%
• Return on Assets: -107.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.05
• Quick Ratio: 5.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.55) per share
• Price / Book: -17.00

Miscellaneous

• Outstanding Shares: 13,640,000
• Free Float: 12,895,000
• Market Cap: $127.53 million
• Optionable: Optionable
• Beta: 1.41